Accuray (ARAY) Beats Q4 Revenue Estimates, BTIG Maintains Buy Rating

Accuray Incorporated (NASDAQ:ARAY) ranks among the top robotics to buy according to analysts. After Accuray Incorporated (NASDAQ:ARAY) reported fiscal fourth-quarter results and fiscal 2026 outlook, BTIG maintained its Buy rating on the radiation therapy company and increased its price target from $4 to $5 on August 14.

Accuray (ARAY) Beats Q4 Revenue Estimates, BTIG Maintains Buy Rating

Photo by Accuray on Unsplash

Accuray’s fiscal fourth-quarter revenue of $127.5 million exceeded consensus projections of $123.8 million, despite a 5% year-over-year decline. Product revenue of $70.7 million, which was over $4 million higher than the forecast, was the main driver of the sales beat, while services revenue of $56.8 million remained as expected.

According to BTIG, Accuray Incorporated (NASDAQ:ARAY) overcame several obstacles during the quarter, such as the temporary suspension of shipments to China and the disruptions caused by Middle East hostilities in the EIMEA region. The firm thinks management has a realistic outlook for fiscal 2026, with room for improvement if macroeconomic headwinds and the tariff situation with China improve.

Accuray Incorporated (NASDAQ:ARAY) that is involved in developing cutting-edge cancer and neuro-radiosurgery solutions. The CyberKnife technology, which treats primary and metastatic malignancies outside the brain, is the company’s most well-known robotic stereotactic radiosurgery and stereotactic body radiation therapy technology.

While we acknowledge the potential of ARAY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARAY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.